1. To describe genomic mechanisms of resistance to immunotherapy in prostate cancer.

2. To highlight a critical role for neutrophils in anti-cancer innate immunity induced by a tyrosine kinase inhibitor.

3. To provide an overview of ongoing co-clinical trial efforts with novel immuno-oncology combinations to target PTEN-deficient cancers

Session date: 
08/14/2017 - 12:00pm to 1:00pm CDT
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Akash Patnaik, MD, PhD, MMSc